Higher Hemoglobin Levels Using Darbepoetin Alfa and Kidney Outcomes in Advanced Chronic Kidney Disease Without Diabetes: a Prespecified Secondary Analysis of the PREDICT Trial

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2023 Jun 8

PMID 37289335

Authors

Shoichi Maruyama

Shimon Kurasawa

Terumasa Hayashi

Masaomi Nangaku

Ichiei Narita

Hideki Hirakata

Kenichiro Tanabe

Satoshi Morita

Yoshiharu Tsubakihara

Enyu Imai

Tadao Akizawa

Affiliations

Soon will be listed here.

Abstract

Background: In the primary analysis of the PREDICT trial, a higher hemoglobin target (11-13 g/dl) with darbepoetin alfa did not improve renal outcomes compared with a lower hemoglobin target (9-11 g/dl) in advanced chronic kidney disease (CKD) without diabetes. Prespecified secondary analyses were performed to further study the effects of targeting higher hemoglobin levels on renal outcomes.

Methods: Patients with an estimated glomerular filtration rate (eGFR) 8-20 ml/min/1.73 m without diabetes were randomly assigned 1:1 to the high- and low-hemoglobin groups. The differences between the groups were evaluated for the following endpoints and cohort sets: eGFR and proteinuria slopes, assessed using a mixed-effects model in the full analysis set and the per-protocol set that excluded patients with off-target hemoglobin levels; the primary endpoint of composite renal outcome, evaluated in the per-protocol set using the Cox model.

Results: In the full analysis set (high hemoglobin, n = 239; low hemoglobin, n = 240), eGFR and proteinuria slopes were not significantly different between the groups. In the per-protocol set (high hemoglobin, n = 136; low hemoglobin, n = 171), the high-hemoglobin group was associated with reduced composite renal outcome (adjusted hazard ratio: 0.64; 95% confidence interval: 0.43-0.96) and an improved eGFR slope (coefficient: + 1.00 ml/min/1.73 m/year; 95% confidence interval: 0.38-1.63), while the proteinuria slope did not differ between the groups.

Conclusions: In the per-protocol set, the high-hemoglobin group demonstrated better kidney outcomes than the low-hemoglobin group, suggesting a potential benefit of maintaining higher hemoglobin levels in patients with advanced CKD without diabetes.

Clinical Trial Registration: Clinicaltrials.gov (identifier: NCT01581073).

References

Iseki K, Iseki C, Ikemiya Y, Fukiyama K . Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996; 49(3):800-5. DOI: 10.1038/ki.1996.111. View

Agodoa L, Appel L, Bakris G, Beck G, BOURGOIGNIE J, Briggs J . Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001; 285(21):2719-28. DOI: 10.1001/jama.285.21.2719. View

Akizawa T, Macdougall I, Berns J, Bernhardt T, Staedtler G, Taguchi M . Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies. Am J Nephrol. 2019; 49(4):271-280. PMC: 6518868. DOI: 10.1159/000499111. View

Macdougall I, Akizawa T, Berns J, Bernhardt T, Krueger T . Effects of Molidustat in the Treatment of Anemia in CKD. Clin J Am Soc Nephrol. 2018; 14(1):28-39. PMC: 6364546. DOI: 10.2215/CJN.02510218. View

Xue J, St Peter W, Ebben J, Everson S, Collins A . Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis. 2002; 40(6):1153-61. DOI: 10.1053/ajkd.2002.36861. View

Bahlmann F, Fliser D . Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens. 2008; 18(1):15-20. DOI: 10.1097/MNH.0b013e32831a9dde. View

Tsubakihara Y, Gejyo F, Nishi S, Iino Y, Watanabe Y, Suzuki M . High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther Apher Dial. 2012; 16(6):529-40. DOI: 10.1111/j.1744-9987.2012.01082.x. View

Parfrey P . Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Anemia in CKD. N Engl J Med. 2021; 385(25):2390-2391. DOI: 10.1056/NEJMe2117100. View

Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H . Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial). Clin Exp Nephrol. 2017; 22(1):78-84. PMC: 5805810. DOI: 10.1007/s10157-017-1427-4. View

10.

Pfeffer M, Burdmann E, Chen C, Cooper M, de Zeeuw D, Eckardt K . A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361(21):2019-32. DOI: 10.1056/NEJMoa0907845. View

11.

Stauffer M, Fan T . Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014; 9(1):e84943. PMC: 3879360. DOI: 10.1371/journal.pone.0084943. View

12.

Hammond F, Lewis A, Elks P . If it's not one thing, HIF's another: immunoregulation by hypoxia inducible factors in disease. FEBS J. 2020; 287(18):3907-3916. PMC: 7362030. DOI: 10.1111/febs.15476. View

13.

Weiner D, Tighiouart H, Vlagopoulos P, Griffith J, Salem D, Levey A . Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol. 2005; 16(6):1803-10. DOI: 10.1681/ASN.2004070597. View

14.

Imai E, Maruyama S, Nangaku M, Hirakata H, Hayashi T, Narita I . Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). Clin Exp Nephrol. 2015; 20(1):71-6. DOI: 10.1007/s10157-015-1133-z. View

15.

Drueke T, Locatelli F, Clyne N, Eckardt K, Macdougall I, Tsakiris D . Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355(20):2071-84. DOI: 10.1056/NEJMoa062276. View

16.

Chertow G, Pergola P, Farag Y, Agarwal R, Arnold S, Bako G . Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021; 384(17):1589-1600. DOI: 10.1056/NEJMoa2035938. View

17.

Walker A, Schneider G, Yeaw J, Nordstrom B, Robbins S, Pettitt D . Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol. 2006; 17(8):2293-8. DOI: 10.1681/ASN.2005020183. View

18.

Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M . Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One. 2020; 15(7):e0236132. PMC: 7371174. DOI: 10.1371/journal.pone.0236132. View

19.

Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T . Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2016; 91(1):227-234. DOI: 10.1016/j.kint.2016.09.015. View

20.

Singh A, Szczech L, Tang K, Barnhart H, Sapp S, Wolfson M . Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355(20):2085-98. DOI: 10.1056/NEJMoa065485. View